Overview

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is compare the relative bioavailability of 500 mg Metformin Hydrochloride Extended Release Tablets by Alpharma with that of 500 mg CLUCOPHAGE® XR Tablets distributed by Bristol-Myers Squibb Company following a single oral dose (1 x 500 mg extended-release tablet) in healthy adult volunteers under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Actavis Inc.
Treatments:
Metformin